North Carolina 2025 Session Status: In Committee Bipartisan · 8 R · 3 D cosponsors

HB 75 — Pharmaceutical Full Disclosure Act.

Last action — Passed 1st Reading

Track this bill free

No card. One bill, free forever — alerts when it moves.

  1. ✓
    Introduced
  2. 2
    In Committee
  3. 3
    Passed House
  4. 4
    Passed Senate
  5. 5
    To Executive
  6. 6
    Enacted

This bill is in committee in the House. Introduced February 10, 2025. It must pass committee before a floor vote.

Next likely step: a committee vote, then a floor vote in the House.

Prognosis

Advancing 42% · moderate confidence

Where this bill stands today.

Odds of enactment

Low

How often bills like it became law.

  • In Committee

    Current position in the legislative process.

  • 12 sponsors

    2 primary, 10 co-sponsors signed on.

  • Bipartisan support

    Sponsored across 2 parties (8 R · 3 D) — cross-party backing.

Prognosis reads this bill's own signals — stage, sponsorship breadth, committee status, recorded votes and cross-state momentum. Odds come from a model trained on which bills have become law.

Bill Text

What changed in the latest version

25 added · 24 removed

Plain-language change summary

In the latest version of House Bill 75, a section was added to clarify what constitutes a "manufacturer" of prescription drugs, specifying that it includes those who repackage drugs for retail sale. This change is important because it aims to hold all parties involved in the production and advertisement of prescription medications accountable for their marketing practices. By ensuring that manufacturers and their affiliates adhere to the same advertising standards, the bill seeks to provide clearer information to consumers about potential side effects, enhancing transparency in pharmaceutical advertising.

→
Previous
Latest
GENERAL ASSEMBLY OF NORTH CAROLINA H.B.
GENERAL ASSEMBLY OF NORTH CAROLINA SESSION 2025 H 1 HOUSE BILL 75 Short Title:
75 Feb 10, 2025 SESSION 2025 HOUSE PRINCIPAL CLERK H D HOUSE BILL DRH30038-NM-21 Short Title:
Representative Warren.
Representatives Warren, Campbell, and Loftis (Primary Sponsors).
For a complete list of sponsors, refer to the North Carolina General Assembly web site.
A BILL TO BE ENTITLED AN ACT TO REQUIRE ADVERTISEMENTS FOR PRESCRIPTION DRUGS TO MORE CLEARLY DISCLOSE RISKS.
Rules, Calendar, and Operations of the House February 11, 2025 A BILL TO BE ENTITLED AN ACT TO REQUIRE ADVERTISEMENTS FOR PRESCRIPTION DRUGS TO MORE CLEARLY DISCLOSE RISKS.
(3) For any side effect thatmust beincludedin anadvertisement for aprescription drug or biological product under section 352(n) or 353(c) of Title 21 of the United States Code, or any federal regulation or rule issued pursuant to Title 21 ofthe UnitedStates Code,theregulated advertisement shall include at least the following details of any clinical trial which evidenced the side effect that is required to be listed:
(3) For anyside effect that must beincludedin anadvertisement for aprescription drug or biological product under section 352(n) or 353(c) of Title 21 of the United States Code, or any federal regulation or rule issued pursuant to Title 21 ofthe UnitedStates Code,theregulated advertisement shall include at least the following details of any clinical trial which evidenced the side effect that is required to be listed:
(3) Manufacturer.
*H75-v-1* General Assembly Of North Carolina Session 2025 (3) Manufacturer.
– A manufacturer of prescription drugs or biological products or an affiliate of the manufacturer or a labeler that receives prescription drugs *DRH30038-NM-21* General Assembly Of North Carolina Session 2025 or biological products from a manufacturer or wholesaler and repackages those drugs or biological products for later retail sale and that has a labeler code from the FDA under 21 Code of Federal Regulations § 207.17.
– A manufacturer of prescription drugs or biological products or an affiliate of the manufacturer or a labeler that receives prescription drugs or biological products from a manufacturer or wholesaler and repackages those drugs or biological products for later retail sale and that has a labeler code from the FDA under 21 Code of Federal Regulations § 207.17.
Page 2 DRH30038-NM-21
Page 2 House Bill 75-First Edition
⬇ Download PDF
View plain text versions (2)

Action History

  1. Passed 1st Reading

  2. Ref To Com On Rules, Calendar, and Operations of the House

  3. Filed

Sponsors

Sponsorship breakdown

Export CSV (upgrade) →

2 sponsors · 10 co-sponsors · 167 not signed on

Sponsors (2)

Co-sponsors (10)

Not signed on (167)

167 members have not signed on to this bill.

Show all 167 →

"Not signed on" means a member has not sponsored or co-sponsored this bill — it does not imply opposition. Members flagged Voted No have a recorded No vote on this bill.

Whip count is in markup. Polling the chamber and every recorded vote this session. Only the first open is slow. It’s instant for you after this. Calling the roll · Tallying · Engrossing

Subjects

healthcare health-insurance
Cross-referencing the record. Reading this bill against every other bill in the corpus by meaning, not keywords. Only the first open is slow. It’s instant for you after this. Matching · Ranking · Engrossing

Frequently asked questions

Who sponsors HB 75?
HB 75 is sponsored by Bill Ward (Republican), Howard Penny, Jr. (Republican), Ben T. Moss, Jr. (Republican), Jeffrey C. McNeely (Republican), Carolyn G. Logan (Democratic), Keith Kidwell (Republican), Pricey Harrison (Democratic), Jonathan L. Almond (Republican), Eric Ager (Democratic), Donnie Loftis (Republican), Campbell, and Harry Warren (Republican).
What is the current status of HB 75?
This bill is in committee in the House. Introduced February 10, 2025. It must pass committee before a floor vote.
Where can I track HB 75?
Track HB 75 free on One Click Politics — get push/email alerts when it moves.

Make your voice heard on HB 75

Find the representatives who decide this bill and tell them where you stand — for yourself, or mobilize your whole list in one click with One Click Politics advocacy software.

Find my representatives → Run a campaign

Stay ahead of HB 75

Last checked for changes 3 months ago · updated continuously

One Click Politics tracks every bill in Congress and all 50 states.

Track this bill →